A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors.

Debashis Sarker, Sophie Glatt, Nieves Díaz et al.|Journal of Clinical Oncology|2022

Cited by 2